Lucintel's latest market report analyzed that FLT3 inhibitor provides attractive opportunities in the midostaurin, gilteritinib, and sorafenib markets. The FLT3 inhibitor market is expected to reach $XX billion by 2028 with a CAGR of 4% to 6%. In this market, type 1 FLT3 inhibitor is the largest segment by therapy, whereas gilteritinib is largest by drug type. Rising research and development...

The global FMS-Like Tyrosine kinase 3 (FLT3) inhibitors market size was USD 405.6 Million in 2021 and is expected to register a revenue CAGR of 14.6% during the forecast period, according to latest analysis by Emergen Research. Rising high-value investments for Research & Development (R&D) initiatives by various major pharmaceutical companies for improvement in therapy...